Clinical trial
MULTICENTER, PROSPECTIVE, OBSERVATIONAL OF ERLOTINIB AS SECOND-LINE TREATMENT IN PATIENTS WITH NON-SMALL CELL (NSCLC) LUNG CANCER WITH PREDOMINANTLY SQUAMOUS HISTOLOGY AND CARRIERS OF THE GENE (EGFR) EPIDERMAL GROWTH FACTOR RECEPTOR NATIVE
NCT02328391 is registered in ClinicalTrials.gov with Grupo Gallego de Cancer de Pulmon as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- MULTICENTER, PROSPECTIVE, OBSERVATIONAL OF ERLOTINIB AS SECOND-LINE TREATMENT IN PATIENTS WITH NON-SMALL CELL (NSCLC) LUNG CANCER WITH PREDOMINANTLY SQUAMOUS HISTOLOGY AND CARRIERS OF THE GENE (EGFR) EPIDERMAL GROWTH FACTOR RECEPTOR NATIVE
- Lead sponsor
- Grupo Gallego de Cancer de Pulmon
- Phase
- Observational
- Overall status
- Unknown status
- Start date
- September 30, 2013
- Completion date
- December 31, 2015
- Enrollment
- 51 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.